The University of Cape Town (UCT) has received a substantial R13 million grant from the Technology Innovation Agency (TIA), marking a significant step forward in addressing one of South Africa's most pressing health challenges: rheumatic heart disease (RHD). This funding will accelerate the development and expansion of UCT's innovative synthetic-leaflet heart valve platform, designed specifically for patients suffering from rheumatic heart valve disease. Led by Professor Johan Scherman from UCT's Department of Cardiothoracic Surgery, the project promises to transform treatment options for a condition that disproportionately affects young people in low-resource settings.

Rheumatic heart disease arises from acute rheumatic fever (ARF), an autoimmune response triggered by untreated group A Streptococcus infections, commonly known as strep throat. Over time, repeated episodes lead to inflammation and scarring of the heart valves, impairing blood flow and causing symptoms ranging from fatigue and shortness of breath to heart failure and stroke. In South Africa, RHD remains a major public health issue despite being largely preventable through penicillin prophylaxis and early diagnosis. Recent studies indicate high prevalence rates, with school-based screening revealing asymptomatic cases at 5 to 30 per 1,000 children in various regions, while symptomatic adult cases contribute to heart failure incidence of around 25 per 100,000 annually, often with high mortality.

🔬 The Burden of Rheumatic Heart Disease in South Africa

South Africa bears a heavy load from RHD, with sub-Saharan Africa accounting for about 23% of global cases. Estimates suggest prevalence rates as high as 10.31 per 1,000 in some populations, driven by overcrowding, poor sanitation, and limited access to primary healthcare. Hospital data from Gauteng Province highlight acute heart failure due to RHD at rates that underscore its persistence, even as overall cardiovascular disease shifts toward non-communicable causes. Young adults under 40 are particularly affected, leading to lost productivity and straining public health systems. UCT researchers have long documented this, with studies showing case fatality rates exceeding 20% for RHD-related admissions.

Prevention strategies, including secondary prophylaxis with benzathine penicillin injections every 21-28 days, have shown promise but face adherence challenges in rural areas. Echo screening programs in schools have identified latent cases, enabling early intervention, yet surgical needs remain unmet due to limited valve options suitable for pediatric and young adult patients.

UCT's Pioneering Research Legacy in Cardiovascular Innovation

UCT has been at the forefront of RHD research for decades, with the Chris Barnard Division of Cardiothoracic Surgery leading efforts since the first human heart transplant in 1967. Professor Peter Zilla and his team have advanced valve technologies tailored to RHD patients, who often require replacements early in life. Mechanical valves, while durable, demand lifelong anticoagulation with warfarin, posing bleeding risks and compliance issues in resource-poor settings. Tissue valves degrade faster in younger patients, necessitating reoperations.

The university's Cardiovascular Research Unit has published extensively on RHD epidemiology, genetics, and interventions. A pan-African study identified genetic loci linked to RHD susceptibility in black Africans, opening doors to precision medicine. Collaborations like the REMEDY registry have informed global guidelines, emphasizing Africa's unique needs.

Birth of Strait Access Technologies (SAT)

In 2008, UCT spun out Strait Access Technologies (SAT), commercializing synthetic polymer heart valves. SAT's flagship innovation uses durable polymeric leaflets, mimicking native valve function without biological tissue vulnerabilities. Early prototypes demonstrated superior hemodynamics in preclinical tests, paving the way for surgical implantation. Previous TIA funding in 2022 boosted low-cost device development, culminating in this latest R13 million award.

SAT's valves target transcatheter aortic valve replacement (TAVR) adaptations for RHD, potentially avoiding open-heart surgery. Professor Scherman's work on hybrid electrospun valves has shown promise in animal models, with human trials on the horizon.

Photo by Zulfugar Karimov on Unsplash

Breaking Down the Synthetic Leaflet Platform

The synthetic leaflet platform employs advanced polymers like polyurethane or silicone elastomers, engineered for flexibility, fatigue resistance, and biocompatibility. Unlike porcine or bovine pericardium, these leaflets resist calcification and degeneration, ideal for patients under 40—who comprise most RHD cases. The step-by-step process involves:

• Material Selection: Biostable polymers tested for long-term durability exceeding 20 years.
• Design Optimization: Computational modeling simulates blood flow, minimizing turbulence and thrombosis.
• Fabrication: Electrospinning creates nanofibrous leaflets mimicking native collagen structure.
• Preclinical Testing: Implantation in sheep models validates function under physiological stresses.
• Clinical Translation: Surgical or transcatheter delivery for mitral/aortic positions.

This technology addresses key limitations: no anticoagulation needed, cost-effective manufacturing, and scalability for African markets. For more on the platform, see UCT's detailed overview here.

Details of the R13 Million TIA Grant

Awarded on April 10, 2026, the grant funds Phase II expansion, including prototype refinement, regulatory approvals, and first-in-human trials. TIA's support underscores South Africa's push for biotech innovation hubs. Scherman noted, "This funding positions UCT to deliver affordable, durable valves to millions affected by RHD." The project spans three years, partnering with SAT for commercialization.

Complementing prior investments, like the 2022 boost for minimally invasive devices, this scales production. Economic modeling suggests potential savings of billions in healthcare costs by reducing reoperations.

Stakeholder Perspectives and Expert Insights

Professor Zilla emphasizes, "RHD patients need valves that last a lifetime; synthetics offer that hope." Cardiologists highlight current mismatches: mechanical valves suit elderly non-RHD patients better, while tissue valves fail young RHD sufferers. Patient advocacy groups welcome the news, citing 350,000 annual global RHD deaths, many preventable.

South African Medical Research Council (SAMRC) data supports urgency, with RHD causing disproportionate morbidity in black communities.

Challenges and Solutions in RHD Valve Therapy

Current challenges include anticoagulation non-compliance (up to 50% in SA), high surgical costs (R200,000+ per valve replacement), and access disparities. The synthetic platform counters these with:

• Anticoagulation-free design reducing stroke/bleed risks.
• Local manufacturing slashing costs by 70%.
• Adaptability for pediatric growth via adjustable frames.

Trials will address durability in high-flow RHD valves. For context on global efforts, the World Heart Federation's criteria guide screening here.

Photo by Zulfugar Karimov on Unsplash

Implications for South African Higher Education

This grant exemplifies UCT's role in translational research, fostering spin-offs like SAT that create jobs and IP. SA universities, including Wits and Stellenbosch, collaborate on RHD genomics and epidemiology. Funding bodies like TIA and NRF prioritize health tech, positioning higher ed as economic drivers. Explore opportunities at AcademicJobs research positions.

Future Outlook: Trials, Scale-Up, and Global Reach

Next milestones: ISO certification by 2027, Phase I trials at Groote Schuur Hospital, market entry by 2030. Partnerships with African Union health initiatives could deploy valves continent-wide. Long-term, this could halve RHD surgery costs, saving lives and boosting SA's medtech sector.

UCT's breakthrough not only advances medicine but inspires the next generation of researchers. For related careers, check SA university jobs.